The Medical Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. The industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on and so forth. The medical instruments space has been benefiting from the ongoing merger and acquisition trend. The smaller and mid-sized industry players have been trying to compete with the big shots through consolidation. This trend is more visible after the pandemic-led downturn. The big players are also attempting to enter new markets by acquiring niche products. Moreover, since the beginning of 2023, this industry has been witnessing massive adoption of artificial intelligence (AI) and the Internet of Medical Things in the form of digital healthcare options in hospitals and other healthcare settings. Digital enhancement, while optimizing costs, proves to be better for clinical outcomes. With an increase in the adoption of digital platforms within the medical device space, robotic surgeries, big-data analytics, bioprinting, 3D printing, electronic health records, predictive analytics, real-time alerting and revenue cycle management services are gaining prominence in the United States. However, the Medical Instruments players are suffering from logistical challenges and higher unit costs. The pandemic-led devastation of the global supply-chain management system and the effects of monetary policy tightening by the Fed to combat a record-high inflation rate and the withdrawal of fiscal support amid high debt are negatively impacting the industry. Our Top Picks We have narrowed our search to five Medical Instruments stocks with strong potential for the rest of 2024. These stocks have seen positive earnings estimate revisions in the last 60 days. Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The chart b elow shows the price performance of our five picks in the past month. Zacks Investment Research Image Source: Zacks Investment Research DexCom Inc. DXCM has benefited from an impressive contribution from the Sensor segment and domestic and international revenue growth were the key catalysts. DXCM’s prospects with Stelo as an OTC monitor for type 2 diabetes bode well. DXCM made continued advancements concerning key strategic objectives and ended the quarter with new patient additions. DXCM’s slew of tie-ups with AID systems are encouraging. A solid international foothold and robust product portfolio augur well. A strong solvency position is an added plus. DexCom has an expected revenue and earnings growth rate of 19.4% and 17.1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.7% over the last 60 days. Hologic Inc. HOLX continues to witness revenue growth with a recovery in procedural volumes and an acceleration in new business lines. HOLX’s GYN Surgical business is registering growth driven by contributions from MyoSure Fluent Fluid Management and Laparoscopy. HOLX’s expanded global installed base of Panthers instruments represents the catalyst for sustained growth in Diagnostics. HOLX’s international business continues to drive strong top-line growth. To streamline its operations and reduce the cost of revenues, Hologic has been adopting strategies that are likely to drive future growth. Hologic has an expected revenue and earnings growth rate of 0.1% and 3%, respectively, for the current year (ending September 2024). The Zacks Consensus Estimate for current-year earnings has improved 0.2% over the last 60 days. Alcon Inc. ALC is witnessing strength in the Surgical and Vision Care segments backed by healthy markets. Within Surgical, ALC continues to gain market share driven by strong consumables and equipment sales. ALC’s flagship lenses, Vivity and PanOptix and monofocal torics continue to lead the category globally. In Vision Care, ALC is registering solid growth, banking on strong sales of its contact lenses and ocular health products. In contact lenses, ALC is successfully executing its strategy of investing in fast-growing market segments. ALC is witnessing a strong uptake of its specialty daily lenses, including DAILIES Total1 Toric, DAILIES Total1 Multifocal and Precision1 Toric. Alcon has an expected revenue and earnings growth rate of 6.1% and 11.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last 60 days. Intuitive Surgical Inc. ISRG has benefited on the back of continued growth in the company’s da Vinci procedure volume, coupled with strong Ion procedure growth. ISRG’s initiative to increase the pricing of procedures should also continue to aid in sales growth in 2024. Improving procedure volume along with better system placements and services across all markets will drive top-line growth of ISRG this year. The launch of da Vinci SP in Europe and da Vinci 5 in the U.S. market should drive ISRG’s system placements higher. Intuitive Surgical has an expected revenue and earnings growth rate of 12.5% and 9.6%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.5% over the last 60 days. Thermo Fisher Scientific Inc. TMO is braving the ongoing tough economic conditions by utilizing the PPI (Practical Process Improvement) Business System, resulting in strong financial performance. TMO’s growth strategy is further bolstered by the introduction of the Axiom PangenomiX Array, a high-throughput array designed for global genomic studies. TMO’s consistent efforts to expand bioproduction purification resin capacity, which is used in the mRNA manufacturing process, look encouraging. TMO continues to prioritize its partnership with customers to drive innovation and improve patient care, which bodes well. A strong solvency position is an added advantage. Thermo Fisher Scientific has an expected revenue and earnings growth rate of 0.2% and 0.5%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.6% over the last 60 days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG):Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO):Free Stock Analysis Report Hologic, Inc. (HOLX):Free Stock Analysis Report Alcon (ALC):Free Stock Analysis Report DexCom, Inc. (DXCM):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...